GUANGZHOU, China, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next-generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended June 30, 2026.

Recent Business Updates

  • Therapy Selection & MRD
    • OncoScreen® BCMatch Tissue Kit has officially entered the Priority Review Channel of the Center for Medical Device Evaluation (CMDE) under the NMPA.
    • CanCatch Custom Kit and CanCatch Custom Kit (cPAS) have officially entered the Special Review Procedure for Innovative Medical Devices of CMDE under the NMPA.
    • In August 2026, the Priority Review Channel application for OncoCompass Target Cancer Mutation Profiling Liquid Kit was resubmitted and subsequently accepted for review.

“After navigating a challenging first quarter, we delivered the anticipated sequential recovery in the second quarter, offsetting the order volatility in the first quarter,” said Mr. Yusheng Han, Chairman and Chief Executive Officer of Burning Rock. “With several products having entered the Priority Review Channel and Special Review Procedure for Innovative Medical Devices of CMDE and new registration certificates expected in the coming quarters, we are confident that we will achieve sustainable and meaningful top‑line growth over the long term.”

Second Quarter 2026 Financial Results

Revenues were RMB134.7 million (US$19.9 million) for the three months ended June 30, 2026, representing a 9.3% decrease from RMB148.5 million for the same period in 2025.

  • Revenue generated from central laboratory business was RMB36.8 million (US$5.4million) for the three months ended June 30, 2026, representing a 10.0% decrease from RMB40.9 million for the same period in 2025, primarily attributable to a decrease in the number of tests, as we continued our transition towards in-hospital business.
  • Revenue generated from in-hospital business was RMB67.1 million (US$9.9 million) for the three months ended June 30, 2026, representing a 7.4% increase from RMB62.5 million for the same period in 2025, driven by an increase in sales volume.
  • Revenue generated from pharma research and development services was RMB30.8 million (US$4.6 million) for the three months ended June 30, 2026, representing a 31.8% decrease from RMB45.1 million for the same period in 2025, primarily attributable to decreased testing services performed for our pharma customers.

Cost of revenues was RMB36.9 million (US$5.5 million) for the three months ended June 30, 2026, representing an 8.6% decrease from RMB40.4 million for the same period in 2025.

Gross profit was RMB97.8 million (US$14.4 million) for the three months ended June 30, 2026, representing a 9.5% decrease from RMB108.1 million for the same period in 2025. Gross margin was 72.6% for the three months ended June 30, 2026, compared to 72.8% for the same period in 2025. By channel, gross margin of central laboratory business was 85.7% for the three months ended June 30, 2026, compared to 87.9% during the same period in 2025, primarily driven by an increased depreciation; gross margin of in-hospital business was 77.1% for the three months ended June 30, 2026, compared to 74.4% during the same period in 2025, primarily attributable to an increase in sales volume to high margin products; gross margin of pharma research and development services was 47.2% for the three months ended June 30, 2026, compared to 56.8% during the same period of 2025, primarily due to a decrease in test volume of higher-margin projects.

Non-GAAP gross profit, which excludes depreciation and amortization expenses, was RMB100.1 million (US$14.8 million) for the three months ended June 30, 2026, representing a 9.4% decrease from RMB110.5 million for the same period in 2025. Non-GAAP gross margin was 74.3% for the three months ended June 30, 2026, compared to 74.4% for the same period in 2025. For more details on these non-GAAP financial measures, please see the table captioned “Reconciliations of GAAP and Non-GAAP Results” set forth at the end of this press release.

Operating expenses were RMB115.8 million (US$17.1 million) for the three months ended June 30, 2026, representing a 3.2% decrease from RMB119.6 million for the same period in 2025. The decrease was primarily driven by business cost control to improve operating efficiency.

  • Research and development expenses were RMB31.2 million (US$4.6 million) for the three months ended June 30, 2026, representing a 37.3% decrease from RMB49.8 million for the same period in 2025, primarily due to a temporary decrease across different research phases.
  • Selling and marketing expenses were RMB47.1 million (US$6.9 million) for the three months ended June 30, 2026, representing a 22.7% increase from RMB38.4 million for the same period in 2025, primarily due to an increase in staff costs.
  • General and administrative expenses were RMB37.5 million (US$5.6 million) for the three months ended June 30, 2026, representing a 19.2% increase from RMB31.4 million for the same period in 2025, primarily due to an increase in allowance for credit loss in relation to accounts receivables, partially offset by a decrease in share-based compensation expenses.

Net loss was RMB18.4 million (US$2.7 million) for the three months ended June 30, 2026, compared to RMB9.7 million for the same period in 2025.

Cash, cash equivalents and restricted cash were RMB419.1 million (US$61.8 million) as of June 30, 2026.

Exchange Rate Information

This press release contains translations of certain Renminbi amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from Renminbi to U.S. dollars and from U.S. dollars to Renminbi are made at a rate of RMB6.7851 to US$1.00, the exchange rate on June 30 2026, set forth in the H.10 statistical release of the Federal Reserve Board. The Company makes no representation that the Renminbi or U.S. dollars amounts referred could be converted into U.S. dollars or Renminbi, as the case may be, at any particular rate or at all.

About Burning Rock

Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, and ii) cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.

For more information about Burning Rock, please visit: ir.brbiotech.com .

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “confident” and similar statements. Burning Rock may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Burning Rock’s beliefs and expectations, are forward-looking statements. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Burning Rock’s control. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. All information provided in this press release is as of the date of this press release, and Burning Rock does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

Non-GAAP Measures

In evaluating the business, the Company considers and uses non-GAAP measures, such as non-GAAP gross profit and non-GAAP gross margin, as supplemental measures to review and assess operating performance and formulate business plans. However, the presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). These non-GAAP financial measures may be different from non-GAAP methods of accounting and reporting used by other companies, including peer companies, and therefore their comparability may be limited.

The Company defines non-GAAP gross profit as gross profit excluding depreciation and amortization. The Company defines non-GAAP gross margin as non-GAAP gross profit divided by its revenue.

The Company believes presenting non-GAAP gross profit and non-GAAP gross margin excluding non-cash impact of depreciation and amortization, in addition to the Company’s GAAP gross profit and gross margin, provides a better understanding of the underlying trends in the Company’s operating business performance.

Reconciliation of these non-GAAP financial measures to the most directly comparable U.S. GAAP measures are set forth at the end of this press release, all of which should be considered when evaluating the Company’s performance.

Contact: [email protected]

Selected Operating Data
As of
June 30, September 30, December 31, March 31, June 30,
2025 2025 2025 2026 2026
In-hospital channel:
Pipeline partner hospitals(1) 30 31 30 30 30
Contracted partner hospitals(2) 63 63 64 64 64
Total number of partner hospitals 93 94 94 94 94


(1) Refers to hospitals that are in the process of establishing in-hospital laboratories, laboratory equipment procurement or installation, staff training or pilot testing using the Company’s products.
(2) Refers to hospitals that have entered into contracts to purchase the Company’s products for use on a recurring basis in their respective in-hospital laboratories the Company helped them establish. Kit revenue is generated from contracted hospitals.


Selected Financial Data
For the three months ended
June 30, September 30, December 31, March 31, June 30,
Revenues 2025 2025 2025 2026 2026
(RMB in thousands)
Central laboratory channel 40,861 36,811 44,025 32,420 36,782
In-hospital channel 62,496 52,847 51,005 52,761 67,145
Pharma research and development channel 45,197 41,959 31,285 22,762 30,838
Total revenues 148,554 131,617 126,315 107,943 134,765

For the three months ended
June 30, September 30, December 31, March 31, June 30,
Revenues by location of contracting customer 2025 2025 2025 2026 2026
(RMB in thousands)
Overseas 37,458 17,214 21,849 8,544 17,878
Chinese mainland 111,096 114,403 104,466 99,399 116,887
Total revenues 148,554 131,617 126,315 107,943 134,765

For the three months ended
June 30, September 30, December 31, March 31, June 30,
Gross profit 2025 2025 2025 2026 2026
(RMB in thousands)
Central laboratory channel 35,937 30,126 39,322 28,761 31,510
In-hospital channel 46,490 37,925 38,388 38,458 51,760
Pharma research and development channel 25,676 30,793 20,856 10,789 14,543
Total gross profit 108,103 98,844 98,566 78,008 97,813

For the three months ended
June 30, September 30, December 31, March 31, June 30,
Share-based compensation expenses 2025 2025 2025 2026 2026
(RMB in thousands)
Cost of revenues 280 301 300 82 141
Research and development expenses (270 ) 73 259 (345 ) 345
Selling and marketing expenses 364 624 748 164 269
General and administrative expenses 2,005 2,831 1,815 1,907 1,244
Total share-based compensation expenses 2,379 3,829 3,122 1,808 1,999


Burning Rock Biotech Limited
Unaudited Condensed Statements of Comprehensive Loss
(in thousands, except for number of shares and per share data)
For the three months ended
June 30, September 30, December 31, March 31, June 30, June 30,
2025
2025
2025
2026
2026
2026
RMB RMB RMB RMB RMB US$
Revenues 148,554 131,617 126,315 107,943 134,765 19,862
Cost of revenues (40,451 ) (32,773 ) (27,749 ) (29,935 ) (36,952 ) (5,446 )
Gross profit 108,103 98,844 98,566 78,008 97,813 14,416
Operating expenses:
Research and development expenses (49,770 ) (41,469 ) (34,866 ) (27,559 ) (31,230 ) (4,603 )
Selling and marketing expenses (38,413 ) (41,808 ) (44,066 ) (41,206 ) (47,141 ) (6,948 )
General and administrative expenses (31,417 ) (31,698 ) (31,672 ) (28,088 ) (37,443 ) (5,518 )
Total operating expenses (119,600 ) (114,975 ) (110,604 ) (96,853 ) (115,814 ) (17,069 )
Loss from operations (11,497 ) (16,131 ) (12,038 ) (18,845 ) (18,001 ) (2,653 )
Interest income 2,226 1,744 1,502 1,261 1,370 202
Interest expense - (15 ) (15 ) (15 ) (15 ) (2 )
Other income (expense), net 387 7 1 294 (199 ) (29 )
Foreign exchange (loss) gain, net (574 ) (2,151 ) (3,960 ) 65 (1,278 ) (188 )
Loss before income tax (9,458 ) (16,546 ) (14,510 ) (17,240 ) (18,123 ) (2,670 )
Income tax expenses (244 ) (212 ) (876 ) (232 ) (287 ) (42 )
Net loss (9,702 ) (16,758 ) (15,386 ) (17,472 ) (18,410 ) (2,712 )
Net loss attributable to Burning Rock Biotech Limited’s shareholders (9,702 ) (16,758 ) (15,386 ) (17,472 ) (18,410 ) (2,712 )
Net loss attributable to ordinary shareholders (9,702 ) (16,758 ) (15,386 ) (17,472 ) (18,410 ) (2,712 )
Loss per share for class A and class B ordinary shares:
Class A ordinary shares - basic and diluted (0.09 ) (0.16 ) (0.15 ) (0.17 ) (0.17 ) (0.02 )
Class B ordinary shares - basic and diluted (0.09 ) (0.16 ) (0.15 ) (0.17 ) (0.17 ) (0.02 )
Weighted average shares outstanding used in loss per share computation:
Class A ordinary shares - basic and diluted 90,357,970 90,416,619 87,444,109 87,871,026 91,279,393 91,279,393
Class B ordinary shares - basic and diluted 17,324,848 17,324,848 17,324,848 17,324,848 17,324,848 17,324,848
Other comprehensive loss, net of tax of nil:
Foreign currency translation adjustments (243 ) (1,724 ) (2,050 ) (3,143 ) (2,971 ) (438 )
Total comprehensive loss (9,945 ) (18,482 ) (17,436 ) (20,615 ) (21,381 ) (3,150 )
Total comprehensive loss attributable to Burning Rock Biotech Limited’s shareholders (9,945 ) (18,482 ) (17,436 ) (20,615 ) (21,381 ) (3,150 )


Burning Rock Biotech Limited
Unaudited Condensed Consolidated Balance Sheets
(In thousands)
As of
December 31, June 30, June 30,
2025 2026 2026
RMB RMB US$
ASSETS
Current assets:
Cash and cash equivalents 478,392 416,818 61,431
Restricted cash 2,696 2,290 338
Accounts receivable, net 169,611 172,768 25,463
Contract assets, net 12,301 9,777 1,441
Inventories, net 48,576 34,131 5,030
Contract costs 8,399 5,597 825
Prepayments and other current assets 18,611 22,636 3,337
Total current assets 738,586 664,017 97,865
Non-current assets:
Property and equipment, net 31,099 31,808 4,688
Operating right-of-use assets 42,774 46,282 6,821
Intangible assets, net 284 233 35
Other non-current assets 7,632 8,271 1,219
Total non-current assets 81,789 86,594 12,763
TOTAL ASSETS 820,375 750,611 110,628


Burning Rock Biotech Limited
Unaudited Condensed Consolidated Balance Sheets (Continued)
(in thousands)
As of
December 31, June 30, June 30,
2025
2026
2026
RMB RMB US$
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable 40,744 17,950 2,646
Deferred revenue 107,819 109,170 16,090
Accrued liabilities and other current liabilities 80,861 68,458 10,090
Customer deposits 592 592 87
Current portion of long-term borrowings 200 200 29
Current portion of operating lease liabilities 16,762 21,172 3,120
Total current liabilities 246,978 217,542 32,062
Non-current liabilities:
Long-term borrowings 1,700 1,600 236
Non-current portion of operating lease liabilities 24,458 22,140 3,263
Other non-current liabilities 11,975 12,248 1,805
Total non-current liabilities 38,133 35,988 5,304
TOTAL LIABILITIES 285,111 253,530 37,366
Shareholders’ equity:
Class A ordinary shares 120 126 19
Class B ordinary shares 21 21 3
Additional paid-in capital 5,010,060 5,013,867 738,953
Treasury stock (57,193 ) (57,193 ) (8,429 )
Accumulated deficits (4,255,607 ) (4,291,489 ) (632,487 )
Accumulated other comprehensive loss (162,137 ) (168,251 ) (24,797 )
Total shareholders’ equity 535,264 497,081 73,262
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY 820,375 750,611 110,628


Burning Rock Biotech Limited
Unaudited Condensed Statements of Cash Flows
(in thousands)
For the six months ended
June 30, June 30, June 30,
2025
2026
2026
RMB RMB US$
Net cash used in operating activities (67,876 ) (51,657 ) (7,613 )
Net cash used in investing activities (1,324 ) (2,841 ) (419 )
Net cash generated from/(used in) financing activities 2,000 (100 ) (15 )
Effect of exchange rate on cash, cash equivalents and restricted cash 62 (7,382 ) (1,088 )
Net decrease in cash, cash equivalents and restricted cash (67,138 ) (61,980 ) (9,135 )
Cash, cash equivalents and restricted cash at the beginning of period 522,162 481,088 70,904
Cash, cash equivalents and restricted cash at the end of period 455,024 419,108 61,769


Burning Rock Biotech Limited
Reconciliations of GAAP and Non-GAAP Results
For the three months ended
June 30, September 30, December 31, March 31, June 30,
2025
2025
2025
2026
2026
(RMB in thousands)
Gross profit:
Central laboratory channel 35,937 30,126 39,322 28,761 31,510
In-hospital channel 46,490 37,925 38,388 38,458 51,760
Pharma research and development channel 25,676 30,793 20,856 10,789 14,543
Total gross profit 108,103 98,844 98,566 78,008 97,813
Add: depreciation and amortization:
Central laboratory channel 456 231 490 412 548
In-hospital channel 389 372 308 228 297
Pharma research and development channel 1,528 1,491 2,057 1,885 1,425
Total depreciation and amortization included in cost of revenues 2,373 2,094 2,855 2,525 2,270
Non-GAAP gross profit:
Central laboratory channel 36,393 30,357 39,812 29,173 32,058
In-hospital channel 46,879 38,297 38,696 38,686 52,057
Pharma research and development channel 27,204 32,284 22,913 12,674 15,968
Total non-GAAP gross profit 110,476 100,938 101,421 80,533 100,083
Non-GAAP gross margin:
Central laboratory channel 89.1 % 82.5 % 90.4 % 90.0 % 87.2 %
In-hospital channel 75.0 % 72.5 % 75.9 % 73.3 % 77.5 %
Pharma research and development channel 60.2 % 76.9 % 73.2 % 55.7 % 51.8 %
Total non-GAAP gross margin 74.4 % 76.7 % 80.3 % 74.6 % 74.3 %